Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.

Kenneth G SaagMichael A BeckerAndrew WheltonBarbara HuntMajin CastilloKrisztina KisfalviLhanoo Gunawardhana

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2019)

Both formulations of febuxostat (XR and IR) were well tolerated and effective in patients with gout and normal or impaired renal function, including patients with severe renal impairment.

Keyphrases

phase iii
double blind
uric acid
open label
clinical trial
placebo controlled
phase ii
early onset
metabolic syndrome